The Technical Analyst
Reviva Pharmaceuticals [RVPH]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Reviva Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-5.63% $3.02
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 84.31 mill |
| EPS: | -1.650 |
| P/E: | -1.830 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 27.92 mill |
| Avg Daily Volume: | 0.313 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.830 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.31x |
| Company: PE -1.830 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.949 (-68.58%) $-2.07 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.68 - 3.36 ( +/- 11.23%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-20 | Saxena Parag | Buy | 585 366 | Pre-Funded Warrant |
| 2023-11-20 | Saxena Parag | Buy | 585 366 | Common Stock Warrant (right to buy) |
| 2023-11-13 | Funtleyder Leslie D. | Buy | 8 200 | Stock Option (right to buy) |
| 2023-11-13 | Patel Purav | Buy | 8 200 | Stock Option (right to buy) |
| 2023-11-13 | Saxena Parag | Buy | 8 200 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 72 transactions |
| Buy: 9 383 157 | Sell: 2 515 186 |
Forecast:
16:00 - $3.04
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.04
Forecast 2: 16:00 - $3.04
Forecast 3: 16:00 - $3.04
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.02 (-5.63% ) |
| Volume | 0.124 mill |
| Avg. Vol. | 0.313 mill |
| % of Avg. Vol | 39.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RVPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $4.32 | N/A | Active |
|---|
RVPH
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Latest Press Releases
2024-04-15 08:30:00 - Press Release
Reviva Announces Fda Alignment On Brilaroxazine Clinical Trials For Nda In Schizophrenia
- fda acceptance of 4-week global registrational phase 3 recover-2 study - - two positive 4-week studies plus a 12-month long-term safety study have potential to support a new drug application (nda) for brilaroxazine in schizophrenia – - topline data from 1-year open-label extension (ole) long-term safety trial expected in q4 2024 - cupertino, calif., april 15, 2024 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, announced today it has gained alignment with the u.s. food and drug administration (fda) on its registrational phase 3 program for brilaroxazine in schizophrenia.
2024-04-15 08:05:00 - Press Release
Reviva Reports Full Year 2023 Financial Results And Recent Business Highlights
– recover-1 phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia –
2024-03-28 08:00:00 - Press Release
Reviva To Present Recover Phase 3 Clinical Trial Data For Brilaroxazine In Schizophrenia At The Sirs 2024 Annual Meeting
Cupertino, calif., march 28, 2024 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, today announced that laxminarayan bhat, ph.d., founder, president, and ceo of reviva will be presenting at the 2024 schizophrenia international research society (sirs) annual meeting, to be held april 3-7, 2024, in florence, italy.
2024-03-26 08:00:00 - Press Release
Reviva To Present Recover Phase 3 Clinical Trial Data For Brilaroxazine In Schizophrenia At The Ascpt 2024 Annual Meeting
Cupertino, calif., march 26, 2024 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, today announced that laxminarayan bhat, ph.d., founder, president, and ceo of reviva will be presenting a poster at the american society for clinical pharmacology & therapeutics (ascpt) 2024 annual meeting, to be held in colorado springs, co, usa on march 27-29, 2023.
2024-03-11 08:00:00 - Press Release
Reviva To Present At The Ubs Virtual Cns Day
Cupertino, calif., march 11, 2024 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, today announced that laxminarayan bhat, ph.d., founder, president, and ceo of reviva will participate in a fireside chat at the ubs virtual cns day, taking place virtually march 18, 2024.
Latest News
2024-03-28 08:00:00 - GlobeNewsWire
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy.
2024-03-26 08:00:00 - GlobeNewsWire
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting, to be held in Colorado Springs, CO, USA on March 27-29, 2023.
2024-03-11 08:00:00 - GlobeNewsWire
Reviva to Present at the UBS Virtual CNS Day
CUPERTINO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a Fireside Chat at the UBS Virtual CNS Day, taking place virtually March 18, 2024.
2024-02-20 08:00:00 - GlobeNewsWire
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
CUPERTINO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 2024 BIO CEO & Investor Conference, taking place February 26-27, 2024, in New York, NY.
2024-01-23 07:32:27 - InvestorPlace
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some victims from walking.
2024-01-10 08:00:00 - Accesswire
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present at the Webull LIVE!
2023-11-30 16:05:00 - GlobeNewsWire
Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
CUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, and Narayan Prabhu, CFO of Reviva, will participate in The Benchmark Company's Discovery One-on-One Investor Conference, taking place December 7, 2023 in New York, NY.
2023-11-02 03:11:38 - Seeking Alpha
Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started
Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo on the primary endpoint. The 15 mg dose of brilaroxazine was numerically superior to placebo on the primary endpoint, but did not reach significance. Reviva Pharmaceuticals plans to start its second phase 3 study, RECOVER-2, in Q1'24 and will need to raise additional funds to support the study.
2023-10-30 07:41:23 - Reuters
Reviva Pharma's schizophrenia drug succeeds in late-stage study
Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study.
2023-09-27 02:48:56 - Seeking Alpha
Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER
Reviva Pharmaceuticals is running a phase 3 study of brilaroxazine in schizophrenia called RECOVER, with results expected in October 2023. A previous phase 2 study showed that brilaroxazine had significant antipsychotic activity, and a potentially differentiated side effect profile versus Abilify. RVPH had $11.2M in cash and cash equivalents at the end of Q2'23, and could fall heavily if the phase 3 study doesn't succeed.